New release of NGINX Application Platform strengthens microservices leadership and provides new capabilities for NGINX as an API gateway, Kubernetes Ingress controller, and service mesh

SAN FRANCISCO-Wednesday, April 4th 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- NGINX, Inc., the company based on the popular open source project and offering a suite of technologies designed to develop and deliver modern applications, today announced new capabilities and major enhancements to its Application Platform – an integrated suite of software technologies that simplify the adoption and deployment of microservices.

Enterprise adoption of microservices has reached a tipping point. More than half of companies in a recent survey indicated they deployed microservices for at least one application, and 26% are doing so in production.* Companies are looking to microservices as a modern application architecture to support digital business efforts. However, ... Read more »

•    Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells

•    Assuming all milestones are met, OSE stands to receive more than €1.1 billion

•    OSE-172, an anti-SIRP-alpha monoclonal antibody, is currently in late stage preclinical development with potential in various cancers

•    With this collaboration, Boehringer Ingelheim strengthens a core pillar of its cancer immunology and immune modulation strategy focusing on novel approaches to treat cancer

INGELHEIM, Germany & NANTES, France-Thursday, April 5th 2018 [ AETOS Wire ]

(BUSINESS WIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, today announced a ... Read more »

SAINT-PREX, Switzerland & ROSEVILLE, Minn.-Thursday, April 5th 2018 [ AETOS Wire ]

    Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product
    CDI is one of the most common healthcare-associated infections in the US, affecting more than 500,000 people and causing approximately 29,000 deaths each year.1
    Ferring’s global capabilities ensure broader patient access to any future approved human microbiome treatments derived from Rebiotix’s Microbiota Restoration Therapy™ (MRT™) drug platform

(BUSINESS WIRE) -- Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that sh ... Read more »

 Dividend of EUR 0.80 per A-share approved

LUXEMBOURG -Thursday, April 5th 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- SES (Euronext Paris and Luxembourg Stock Exchange: SESG) held its Annual General Meeting (AGM) today in Betzdorf, Luxembourg.

The shareholders approved all proposed resolutions, notably the company's 2017 accounts and the proposed dividend of EUR 0.80 per A-share, which will be paid to shareholders on 25 April 2018.

Further to the decision to reduce the number of directors from 18 to 15, shareholders re-elected five new directors for a three year term: Serge Allegrezza, Hadelin de Liedekerke Beaufort, Conny Kullman, Jean-Paul Senninger and Katrin Wehr-Seiter.

Following the shareholders’ meeting, the Board of Directors re-elected Mr Romain Bausch as Chairman as well as Mr François Tesch and Mr Jean-Paul Zens as Vice Chairmen.

The 2017 Annual Report is available for download at: http://www.ses.com ... Read more »